Pr. Nicolas GIRERD
10
5
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial
Role: lead
Relationship Between 24-hour Blood Pressure Variability and FRagility in the Elderly Patient
Role: lead
PAthwAy of Dyspneic patIent in Emergency in France
Role: lead
PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes
Role: lead
- 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF
Role: lead
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
Role: lead
Machine Learning Approach Based on Echocardiographic Data to Improve Prediction of Cardiovascular Events in Hypertrophic Cardiomyopathy
Role: lead
PAthwAy of Dyspneic patIent in Emergency in the North-east Region (North-East PArADIsE)
Role: lead
Chronic Heart Failure - COngestion eValuation
Role: lead
CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)
Role: lead
All 10 trials loaded